Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027. Patients who are more obese may ultimately do better with Zepbound, said ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

Trizepatide (Zepbound), on the other hand, mimics two different hormones — GLP-1 and GIP — both of which the body produces after one eats. GIP bolsters how the body processes sugar and fat.

The company is studying eloralintide alone and in combination with Zepbound — similar to the approach Novo is taking with its next-generation drug CagriSema, which combines an amylin component ...

Novo Nordisk shares slump after study comes out in favor of Zepbound. Last Updated: May 12, 2025 at 9:43 a.m. ET First Published: May 12, 2025 at 6:20 a.m. ET. Share. Resize. Listen ...